We are live on ! Find out more

Unicycive Therapeutics

UNCY

Market cap $143M

5.15 USD

-0.14

2.65%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

5.23

+0.08

1.55%

1 day

-2.65%

5 days

0.39%

1 month

-6.53%

3 months

-27.67%

6 months

-26.53%

Year to date

-11.21%

1 year

30.71%

5 years

-81.8%

10 years

-91.2%

About: Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.

Employees: 22

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Unicycive (UNCY) To Contact Him Directly To Discuss Their Options

UNICYCIVE INVESTOR ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Unicycive Therapeutics, Inc. and Encourages Investors to Contact the Firm

DEADLINE ALERT for HYLN, HIMS, UNCY, TBLA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.

DEADLINE ALERT for HYLN, HIMS, UNCY, TBLA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

Unicycive's annual report warned only that the FDA "could ask us to supplement our submissions," while a securities class action alleges the Company never disclosed that it had not inspected the third-party manufacturer whose unresolved cGMP deficiencies triggered a second Complete Response Letter and a 39.1% single-day loss for UNCY shareholders.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. Lawsuit - UNCY

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming November 2, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) securities between December 29, 2025 and June 29, 2026 inclusive (the “Class Period”).

Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Unicycive (UNCY) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/2/2026

Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

NEW YORK, Sept. 14, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the "Class Period").

UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit

UNCY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Unicycive To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Unicycive between December 29, 2025 and June 29, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - September 13, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) and reminds investors of the November 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

UNCY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026

ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

NEW YORK, Sept. 13, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between December 29, 2025 and June 29, 2026, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 2, 2026.

ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - UNCY

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, Sept. 11, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Unicycive Therapeutics, Inc. IF YOU SUFFERED A LOSS ON YOUR UNICYCIVE THERAPEUTICS, INC.

Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors with Significant Losses to Contact the Firm Before November 2, 2026

New York, New York--(Newsfile Corp. - September 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ: UNCY) on behalf of investors that purchased or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Unicycive and have suffered losses, you may CLICK HERE to contact us.

Kaplan Fox Encourages Unicycive Therapeutics, Inc. (UNCY) Investors with Significant Losses to Contact the Firm Before November 2, 2026

See News Rankings

Price charts implemented using Lightweight Charts™